New potential anticancer agent of carborane derivatives: Selective cellular interaction and activity of ferrocene-substituted dithio- o -carborane conjugates

Bioconjugate Chemistry

Volumn 22, Issue 1, 2011, Pages 16-25

  Wu, Chunhui ^a   Ye, Hongde ^b   Bai, Wenjuan ^b   Li, Qingning ^a   Guo, Dadong ^a   Lv, Gang ^a   Yan, Hong ^b   Wang, Xuemei ^a  

^a SOUTHEAST UNIVERSITY   (China)

^b NANJING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CULTURE; CELLS; DISEASES; EFFICIENCY; ELECTROCHEMISTRY; IRON COMPOUNDS; REDOX REACTIONS;

BONDING MODES; CARBORANE DERIVATIVES; CARBORANES; CELLULAR ACTIVITIES; CELLULAR INTERACTION; FERROCENES; ORGANOMETALLIC COMPLEX; POTENTIAL ANTICANCER AGENTS; SYNTHESISED; THERAPEUTIC AGENTS;

ORGANOMETALLICS;

ANTINEOPLASTIC AGENT; CARBORANE DERIVATIVE; FERROCENE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CARCINOMA CELL; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL GROWTH; CELL INTERACTION; CELL PROLIFERATION; DRUG CONJUGATION; DRUG SELECTIVITY; DRUG SYNTHESIS; ELECTROCHEMICAL ANALYSIS; HUMAN; HUMAN CELL; HYDROPHOBICITY; IC 50; REAL TIME CELL ELECTRONIC SENSING;

EID: 78751629456     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/bc100158b     Document Type: Article

References (55)

1. Rosenberg, B., VanCamp, L., Trosko, J. E., and Mansour, V. H. (1969) Platinum compounds: a new class of potent antitumour agents Nature 222, 385-386
2. Alama, A., Tasso, B., Novelli, F., and Sparatore, F. (2009) Organometallic compounds in oncology: implications of novel organotins as antitumor agents Drug Discovery Today 14, 500-508
3. Hartinger, C. G. and Dyson, P. J. (2009) Bioorganometallic chemistry-from teaching paradigms to medicinal applications Chem. Soc. Rev. 38, 391-401
4. van Staveren, D. R. and Metzler-Nolte, N. (2004) Bioorganometallic chemistry of ferrocene Chem. Rev. 104, 5931-5986
5. Fouda, M. F. R., Abd-Elzaher, M. M., Abdelsamaia, R. A., and Labib, A. A. (2007) On the medicinal chemistry of ferrocene Appl. Organometal. Chem. 21, 613-625
6. Fish, R. H. and Jaouen, G. (2003) Bioorganometallic chemistry: structural diversity of organometallic complexes with bioligands and molecular recognition studies of several supramolecular hosts with biomolecules, alkali-metal ions, and organometallic pharmaceuticals Organometallics 22, 2166-2177
7. Caldwell, G., Meirim, M. G., Neuse, E. W., and van Rensburg, C. E. J. (1998) Antineoplastic activity of polyaspartamide-ferrocene conjugates Appl. Organometal. Chem. 12, 793-799
8. Biot, C., Glorian, G., Maciejewski, L. A., Brocard, J. S., Domarle, O., Blampain, G., Millet, P., Georges, A. J., Abessolo, H., Dive, D., and Lebibi, J. (1997) Synthesis and antimalarial activity in vitro and in vivo of a new ferrocene-chloroquine analogue J. Med. Chem. 40, 3715-3718
9. Biot, C., François, N., Maciejewski, L., Brocard, J., and Poulain, D. (2000) Synthesis and antifungal activity of a ferrocene-fluconazole analogue Bioorg. Med. Chem. Lett. 10, 839-841
10. Chantson, J. T., Falzacappa, M. V. V., Crovella, S., and Metzler-Nolte, N. (2006) Solid-phase synthesis, characterization, and antibacterial activities of metallocene-peptide bioconjugates ChemMedChem 1, 1268-1274
11. Gopal, Y. N. V., Jayaraju, D., and Kondapi, A. K. (2000) Topoisomerase II poisoning and antineoplastic action by DNA-nonbinding diacetyl and dicarboxaldoxime derivatives of ferrocene Arch. Biochem. Biophys. 376, 229-235
12. Köpf-Maier, P., Köpf, H., and Neuse, E. W. (1984) Ferricenium complexes: a new type of water-soluble antitumor agent J. Cancer Res. Clin. Oncol. 108, 336-340
13. Tabbi, G., Cassino, C., Cavigiolio, G., Colangelo, D., Ghiglia, A., Viano, I., and Osella, D. (2002) Water stability and cytotoxic activity relationship of a series of ferrocenium derivatives. ESR insights on the radical production during the degradation process J. Med. Chem. 45, 5786-5796
14. Osella, D., Ferrali, M., Zanello, P., Laschi, F., Fontani, M., Nervi, C., and Cavigiolio, G. (2000) On the mechanism of the antitumor activity of ferrocenium derivatives Inorg. Chim. Acta 306, 42-48
15. Kovjazin, R., Eldar, T., Patya, M., Vanichkin, A., Lander, H. M., and Novogrodsky, A. (2003) Ferrocene-induced lymphocyte activation and anti-tumor activity is mediated by redox-sensitive signaling FASEB J. 17, 467-469
16. Jaouen, G., Top, S., Vessières, A., Leclercq, G., and McGlinchey, M. J. (2004) The first organometallic selective estrogen receptor modulators (SERMs) and their relevance to breast cancer Curr. Med. Chem. 11, 2505-2517
17. Hillard, E., Vessières, A., Thouin, L., Jaouen, G., and Amatore, C. (2006) Ferrocene-mediated proton-coupled electron transfer in a series of ferrocifen-type breast cancer drug candidates Angew. Chem., Int. Ed. 45, 285-290
18. Vessières, A., Top, S., Pigeon, P., Hillard, E., Boubeker, L., Spera, D., and Jaouen, G. (2005) Modification of the estrogenic properties of diphenols by the incorporation of ferrocene. Generation of antiproliferative effects in vitro J. Med. Chem. 48, 3937-3940
19. Hillard, E., Vessières, A., Le Bideau, F., Plazuk, D., Spera, D., Huché, M., and Jaouen, G. (2006) A series of unconjugated ferrocenyl phenols: prospects as anticancer agents ChemMedChem 1, 551-559
20. Hillard, E. A., Pigeon, P., Vessières, A., Amatore, C., and Jaouen, G. (2007) The influence of phenolic hydroxy substitution on the electron transfer and anti-cancer properties of compounds based on the 2-ferrocenyl-1-phenyl-but-1-ene motif Dalton Trans. 5073-5081
21. Top, S., Thibaudeau, C., Vessières, A., Brulé, E., Le Bideau, F., Joerger, J.-M., Plamont, M.-A., Samreth, S., Edgar, A., Marrot, J., Herson, P., and Jaouen, G. (2009) Synthesis and structure activity relationship of organometallic steroidal androgen derivatives Organometallics 28, 1414-1424
22. Payen, O., Top, S., Vessières, A., Brulé, E., Plamont, M.-A., McGlinchey, M. J., Müller-Bunz, H., and Jaouen, G. (2008) Synthesis and structure-activity relationships of the first ferrocenyl-aryl-hydantoin derivatives of the nonsteroidal antiandrogen nilutamide J. Med. Chem. 51, 1791-1799
23. Ferreira, A. P., Ferreira da Silva, J. L., Duarte, M. T., Minas da Piedade, M. F., Robalo, M. P., Harjivan, S. G., Marzano, C., Gandin, V., and Marques, M. M. (2009) Synthesis and characterization of new organometallic benzo[ b ]thiophene derivatives with potential antitumor properties Organometallics 28, 5412-5423
24. Plażuk, D., Vessières, A., Hillard, E. A., Buriez, O., Labbé, E., Pigeon, P., Plamont, M.-A., Amatore, C., Zakrzewski, J., and Jaouen, G. (2009) A [3]Ferrocenophane polyphenol showing a remarkable antiproliferative activity on breast and prostate cancer cell lines J. Med. Chem. 52, 4964-4967
25. Auzias, M., Therrien, B., Süss-Fink, G., Štì pnièka, P., Ang, W. H., and Dyson, P. J. (2008) Ferrocenoyl pyridine arene ruthenium complexes with anticancer properties: synthesis, structure, electrochemistry, and cytotoxicity Inorg. Chem. 47, 578-583
26. Henderson, W. and Alley, S. R. (2001) Platinum(II) complexes containing ferrocene-derived phosphonate ligands; synthesis, structural characterisation and antitumour activity Inorg. Chim. Acta 322, 106-112
27. Viotte, M., Gautheron, B., Kubicki, M. M., Nifantev, I. E., and Fricker, S. P. (1995) Synthesis, structure of nitrogen-containing phosphinogold(I) ferrocenes. In vitro activity against bladder and colon carcinoma cell lines Met.-Based Drugs 2, 311-326
28. Shago, R. F., Swarts, J. C., Kreft, E., and Van Rensburg, C. E. J. (2007) Antineoplastic activity of a series of ferrocene-containing alcohols Anticancer Res. 27, 3431-3434
29. Gao, L. M., Hernández, R., Matta, J., and Meléndez, E. (2009) Synthesis, structure, electrochemistry, and cytotoxic properties of ferrocenyl ester derivatives Met. -Based Drugs 2009, 420784 doi:10.1155/2009/ 420784
30. Valliant, J. F., Guenther, K. J., King, A. S., Morel, P., Schaffer, P., Sogbein, O. O., and Stephenson, K. A. (2002) The medicinal chemistry of carboranes Coord. Chem. Rev. 232, 173-230
31. Soloway, A. H., Tjarks, W., Barnum, B. A., Rong, F.-G., Barth, R. F., Codogni, I. M., and Wilson, J. G. (1998) The chemistry of neutron capture therapy Chem. Rev. 98, 1515-1562
32. Primus, F. J., Pak, R. H., Rickard-Dickson, K. J., Szalai, G., Bolen, J. L., Jr., Kane, R. R., and Hawthorne, M. F. (1996) Bispecific antibody mediated targeting of nido -carboranes to human colon carcinoma cells Bioconjugate Chem. 7, 532-535
33. Thirumamagal, B. T. S., Zhao, X. B., Bandyopadhyaya, A. K., Naranyanasamy, S., Johnsamuel, J., Tiwari, R., Golightly, D. W., Patel, V., Jehning, B. T., Backer, M. V., Barth, R. F., Lee, R. J., Backer, J. M., and Tjarks, W. (2006) Receptor-targeted liposomal delivery of boron-containing cholesterol mimics for boron neutron capture therapy (BNCT) Bioconjugate Chem. 17, 1141-1150
34. Miyajima, Y., Nakamura, H., Kuwata, Y., Lee, J.-D., Masunaga, S., Ono, K., and Maruyama, K. (2006) Transferrin-loaded nido -carborane liposomes: tumor-targeting boron delivery system for neutron capture therapy Bioconjugate Chem. 17, 1314-1320
35. Armstrong, A. F. and Valliant, J. F. (2007) The bioinorganic and medicinal chemistry of carboranes: from new drug discovery to molecular imaging and therapy Dalton Trans. 4240-4251
36. Lesnikowski, Z. J. (2007) Boron units as pharmacophores-new applications and opportunities of boron cluster chemistry Collect. Czech. Chem. Commun. 72, 1646-1658
37. Ogawa, T., Ohta, K., Yoshimi, T., Yamazaki, H., Suzuki, T., Ohta, S., and Endo, Y. (2006) m -Carborane bisphenol structure as a pharmacophore for selective estrogen receptor modulators Bioorg. Med. Chem. Lett. 16, 3943-3946
38. Goto, T., Ohta, K., Suzuki, T., Ohta, S., and Endo, Y. (2005) Design and synthesis of novel androgen receptor antagonists with sterically bulky icosahedral carboranes Bioorg. Med. Chem. 13, 6414-6424
39. Endo, Y., Iijima, T., Yaguchi, K., Kawachi, E., Inoue, N., Kagechika, H., Kubo, A., and Itai, A. (2001) Structure-activity study of retinoid agonists bearing substituted dicarba- closo -dodecaborane. Relation between retinoidal activity and conformation of two aromatic nuclei Bioorg. Med. Chem. Lett. 11, 1307-1311
40. Endo, Y., Yoshimi, T., Kimura, K., and Itai, A. (1999) Protein kinase C modulators bearing dicarba- closo -dodecaborane as a hydrophobic pharmacophore Bioorg. Med. Chem. Lett. 9, 2561-2564
41. Valliant, J. F., Schaffer, P., Stephenson, K. A., and Britten, J. F. (2002) Synthesis of boroxifen, a nido-carborane analogue of tamoxifen J. Org. Chem. 67, 383-387
42. 6-based photosensitizers: synthesis, binding to albumin and antitumour efficacy Bioorg. Med. Chem. 17, 1297-1306
43. Hao, E. H., Jensen, T. J., Courtney, B. H., and Vicente, M. G. H. (2005) Synthesis and cellular studies of porphyrin-cobaltacarborane conjugates Bioconjugate Chem. 16, 1495-1502
44. Sibrian-Vazquez, M., Hao, E. H., Jensen, T. J., and Vicente, M. G. H. (2006) Enhanced cellular uptake with a cobaltacarborane-porphyrin-HIV-1 Tat 48-60 conjugate Bioconjugate Chem. 17, 928-934
45. Olshevskaya, V. A., Zaitsev, A. V., Luzgina, V. N., Kondratieva, T. T., Ivanov, O. G., Kononova, E. G., Petrovskii, P. V., Mironov, A. F., Kalinin, V. N., Hofmannd, J., and Shtil, A. A. (2006) Novel boronated derivatives of 5,10,15,20-tetraphenylporphyrin: synthesis and toxicity for drug-resistant tumor cells Bioorg. Med. Chem. 14, 109-120
46. King, R. B. (1966) Organometallic chemistry of the transition metals. XI. Some new cyclopentadienyl derivatives of cobalt and rhodium Inorg. Chem. 5, 82-87
47. 10) Organometallics 18, 2738-2740
48. Xu, B. H., Peng, X. Q., Li, Y. Z., and Yan, H. (2008) Reactions of 16e CpCo half-sandwich complexes containing a chelating 1,2-dicarba- closo -dodecaborane-1,2-dichalcogenolate ligand with ethynylferrocene and dimethyl acetylenedicarboxylate Chem. - Eur. J. 14, 9347-9356
49. Xu, B. H., Peng, X. Q., Xu, Z. W., Li, Y. Z., and Yan, H. (2008) Cobalt(III)-mediated disulfuration and hydrosulfuration of alkynes Inorg. Chem. 47, 7928-7933
50. Noor, F., Kinscherf, R., Bonaterra, G. A., Walczak, S., Wölfl, S., and Metzler-Nolte, N. (2009) Enhanced cellular uptake and cytotoxicity studies of organometallic bioconjugates of the NLS Peptide in HepG2 Cells ChemBioChem 10, 493-502
51. 5]-enkephalin derivatives in an in vitro model system ChemBioChem 10, 1852-1860
52. Khar, A. and Ali, A. M. (1987) Serum protects HeLa cells from antiestrogen effects in culture Eur. J. Cancer Clin. Oncol. 23, 761-763
53. Xi, B., Yu, N. C., Wang, X. B., Xu, X., and Abassi, Y. A. (2008) The application of cell-based label-free technology in drug discovery Biotechnol. J. 3, 484-495
54. Mu, Q. X., Du, G. Q., Chen, T. S., Zhang, B., and Yan, B. (2009) Suppression of human bone morphogenetic protein signaling by carboxylated single-walled carbon nanotubes ACS Nano 3, 1139-1144
55. Zhu, J., Wang, X. B., Xu, X., and Abassi, Y. A. (2006) Dynamic and label-free monitoring of natural killer cell cytotoxic activity using electronic cell sensor arrays J. Immunol. Methods 309, 25-33